ERTACZO- sertaconazole nitrate cream

Ertaczo by

Drug Labeling and Warnings

Ertaczo by is a Prescription medication manufactured, distributed, or labeled by Lacer Pharma, LLC, DPT Laboratories, Ltd.. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS AND USAGE

    ERTACZO ® cream, 2%, is indicated for the topical treatment of interdigital tinea pedis in immunocompetent adult and pediatric patients 12 years of age and older caused by Trichophyton rubrum, Trichophyton mentagrophytes,and Epidermophyton floccosum.

  • 2 DOSAGE AND ADMINISTRATION

    • Apply ERTACZO cream, 2% twice daily for 4 weeks. Apply a sufficient amount of ERTACZO cream, 2% to cover both the affected areas between the toes and the immediately surrounding healthy skin.
    • Use ERTACZO cream, 2% for the full treatment time recommended by the physician, even though symptoms may have improved.
    • Dry the affected area(s) thoroughly before application, if using ERTACZO cream, 2% after bathing.
    • Wash hands after use.
    • Avoid the use of occlusive dressings or wrappings.
    • For topical use.
    • Not for ophthalmic, oral, or intravaginal use.
  • 3 DOSAGE FORMS AND STRENGTHS

    Cream, 2%. Each gram of ERTACZO cream, 2%, contains 17.5 mg of sertaconazole (as sertaconazole nitrate, 20 mg) in a white cream base.

  • 4 CONTRAINDICATIONS

    None.

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Local Adverse Reactions

    If irritation develops, discontinue treatment and institute appropriate therapy.

    Physicians should exercise caution when prescribing ERTACZO cream, 2%, to patients known to be sensitive to azole antifungals since cross-reactivity may occur.

  • 6 ADVERSE REACTIONS

    6.1 Clinical Trials Experience

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

    In clinical trials, cutaneous adverse events occurred in 7 of 297 (2%) subjects (2 of them severe) receiving ERTACZO cream, 2%, and in 7 of 291 (2%) subjects (2 of them severe) receiving vehicle. These reported cutaneous adverse events included contact dermatitis, dry skin, burning skin, and application site skin tenderness.

    In a dermal sensitization trial, 8 of 202 evaluable subjects tested with ERTACZO cream, 2%, and 4 of 202 evaluable subjects tested with vehicle exhibited a erythematous reaction in the challenge phase. There was no evidence of cumulative irritation or contact sensitization in a repeated insult patch test involving 202 healthy volunteers.

    6.2 Postmarketing Experience

    The following adverse reactions have been identified during post-approval use of ERTACZO cream, 2%. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

    Cutaneous adverse events:erythema, pruritus, vesiculation, desquamation, and hyperpigmentation.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    There are no available data on ERTACZO cream, 2% use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal reproduction studies, there were no adverse developmental effects observed with oral administration of sertaconazole nitrate to pregnant rats and rabbits during organogenesis at doses 40 and 80 times, respectively, the maximum recommended human dose (MRHD) based on body surface area (BSA) comparison. In rats, when maternal dosing was continued until weaning, a reduction in live birth indices and an increase in the number of still-born pups was observed at doses 20 and 40 times the MRHD based on BSA comparison ( see Data).

    The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of major birth defects, loss and other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

    Data

    Animal Data

    Animal embryofetal development studies have not been conducted with ERTACZO cream, 2%. Embryofetal development studies performed in pregnant rats and rabbits administered oral doses of sertaconzaole nitrate up to 160 mg/kg/day (40 times [rats] and 80 times [rabbits] the MRHD based on a BSA comparison) during the period of organogenesis revealed no malformations or embryofetal developmental toxicity. In a pre- and postnatal development study, pregnant rats were administered oral doses of sertaconazole nitrate from pregnancy day 6 to lactation day 20. A reduction in live birth indices and an increase in the number of still-born pups were seen at doses 20 and 40 times the MRHD based on BSA comparison.

    8.2 Lactation

    Risk Summary

    There are no data available on the presence of sertaconazole in human or animal milk, its effects on the breastfed infant, or its effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ERTACZO cream, 2% and any potential adverse effects on the breastfed infant from ERTACZO cream, 2% or from the underlying maternal condition.

    8.4 Pediatric Use

    The safety and effectiveness of ERTACZO cream, 2%, have not been established in pediatric patients younger than 12 years of age.

    8.5 Geriatric Use

    Clinical trials of ERTACZO cream, 2%, did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

  • 11 DESCRIPTION

    ERTACZO (sertaconazole nitrate) cream, 2%, is for topical application. It contains the azole antifungal, sertaconazole nitrate. Sertaconazole nitrate contains one asymmetric carbon atom and exists as a racemic mixture of equal amounts of R and S enantiomers.

    Sertaconazole nitrate is designated chemically as (±)-1-[2,4-dichloro-β-[(7-chlorobenzo-[ b]thien-3-yl)methoxy]phenethyl]imidazole nitrate. It has a molecular weight of 500.8. The molecular formula is C 20H 15Cl 3N 2OS ● HNO 3, and the structural formula is as follows:

    Sertaconzole nitrate chemical structure

    Sertaconazole nitrate is a white or almost white powder. It is practically insoluble in water, soluble in methanol, and sparingly soluble in alcohol and in methylene chloride. Each gram of ERTACZO cream, 2%, contains 17.5 mg of sertaconazole (as sertaconazole nitrate, 20 mg) in a white cream base of ethylene glycol, glyceryl isostearate, glycolized saturated glycerides, light mineral oil, methylparaben, polyethylene glycol palmitostearate, polyoxyethylened saturated glycerides, purified water, and sorbic acid.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Sertaconazole nitrate is an azole antifungal [see Clinical Pharmacology (12.4)] .

    12.2 Pharmacokinetics

    In a multiple-dose pharmacokinetic trial that included 5 male subjects with interdigital tinea pedis (range of diseased area, 42 - 140 cm 2; mean, 93 cm 2), ERTACZO cream, 2%, was topically applied every 12 hours for a total of 13 doses to the diseased skin (0.5 g sertaconazole nitrate per 100 cm 2). Sertaconazole concentrations in plasma measured by serial blood sampling for 72 hours after the thirteenth dose were below the limit of quantitation (2.5 ng/mL) of the analytical method used.

    12.3 Microbiology

    Mechanism of Action

    Sertaconazole, an azole antifungal agent, inhibits fungal cytochrome P-450-mediated 14 alpha-lanosterol demethylase enzyme. This enzyme functions to convert lanosterol to ergosterol. Ergosterol is a key component of fungal cell membranes and lack of this component leads to fungal cell injury by leakage of key constituents in the cytoplasm from the cell.

    Activity In Vitro and in Clinical Infections

    Sertaconazole nitrate has been shown to be active against isolates of the following microorganisms in clinical infections [see Indications and Usage (1)] :

    • Trichophyton rubrum
    • Trichophyton mentagrophytes
    • Epidermophyton floccosum
  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    In a 2-year rat dermal carcinogenicity study, topical administration of sertaconazole nitrate cream did not increase the number of neoplastic lesions compared to control animals, at sertaconazole nitrate doses of up to 800 mg/kg/day (200 times the MRHD based on a BSA comparison).

    No clastogenic potential was observed in a mouse micronucleus test. Sertaconazole nitrate was nonclastogenic in the in vivo mouse sister chromatid exchange assay. There was no evidence that sertaconazole nitrate induced unscheduled DNA synthesis in primary rat hepatocyte cultures.

    Rats treated orally with up to 160 mg/kg/day of sertaconazole nitrate (40 times the MRHD based on a BSA comparison), exhibited no toxicity or adverse effects on reproductive performance or fertility in male or female rats.

  • 14 CLINICAL STUDIES

    In two randomized, double-blind clinical trials, subjects 12 years and older with interdigital tinea pedis applied either ERTACZO cream, 2%, or vehicle, twice daily for 4 weeks. Subjects with moccasin-type (plantar) tinea pedis and/or onychomycosis were excluded from the trial. Two weeks after completion of therapy (6 weeks after beginning therapy), subjects were evaluated for signs and symptoms related to interdigital tinea pedis.

    Treatment outcomes are summarized in the table below.

    Treatment Outcomes as Percent (%) of Total Subjects with Interdigital Tinea Pedis
    Trial 1Trial 2
    SertaconazoleVehicleSertaconazoleVehicle

    Complete Cure*(Primary
    Efficacy Variable)

    13/99
    (13.1%)

    3/92
    (3.3%)

    28/103
    (27.2%)

    5/103
    (4.9%)

    Effective Treatment**

    32/99
    (32.3%)

    11/92
    (12.0%)

    52/103
    (50.5%)

    16/103
    (15.5%)

    Mycological Cure***

    49/99
    (49.5%)

    18/92
    (19.6%)

    71/103
    (68.9%)

    20/103
    (19.4%)

    * Complete Cure – Patients who had complete clearing of signs and symptoms and Mycological Cure.
    ** Effective Treatment – Patients who had minimal residual signs and symptoms of interdigital tinea pedis and Mycological Cure.
    *** Mycological Cure – Patients who had both negative microscopic KOH preparation and negative fungal culture.

    In clinical trials, complete cure in ERTACZO cream, 2%-treated subjects was achieved in 32 of 160 (20%) subjects with Trichophyton rubrum, in 7 of 28 (25%) subjects with Trichophyton mentagrophytes, and in 1 of 13 (15%) subjects with Epidermophyton floccosum.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    ERTACZO cream, 2%, is white in color and supplied in tubes in the following size:

    60-gram tube NDC: 73159-004-60

    Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

  • 17 PATIENT COUNSELING INFORMATION

    Advise the patient to read the FDA-approved patient labeling (Patient Information).

    Instruct the patient of the following:

    Administration Instructions

    • ERTACZO cream, 2% is for topical use only.
    • Avoid contact with the eyes, mouth, vagina, and other mucous membranes.
    • Dry the affected area(s) thoroughly before application, if using ERTACZO cream, 2% after bathing.
    • Wash hands after use.
    • Use the medication for the full treatment time recommended by the physician, even though symptoms may have improved.
    • Avoid the use of occlusive dressings unless otherwise directed by the physician [see Dosage and Administration ( 2)] .

    Local Adverse Reactions

    • Inform the physician if the area of application shows signs of increased irritation, redness, itching, burning, blistering, swelling, or oozing [see Warnings and Precautions ( 5.1)] .

    Distributed by:
    Lacer Pharma, LLC
    Biloxi, MS 39532 USA

    Manufactured by:
    DPT Laboratories, Ltd.
    San Antonio, TX 78215

    ERTACZO is a trademark of Lacer Pharma, LLC

    141329

  • Patient Package Insert

    PATIENT INFORMATION

    ERTACZO®(er-tack-zo)

    (sertaconazole nitrate) cream

    Important information: ERTACZO cream is for use on skin only.Do not use ERTACZO cream in your eyes, mouth, or vagina.

    What is ERTACZO cream?

    ERTACZO cream is a prescription medicine used on the skin (topical) to treat athlete’s foot that is between the toes (interdigital tinea pedis) in adults and children 12 years of age and older with normal immune systems.

    It is not known if ERTACZO cream is safe and effective in children younger than 12 years of age.

    Before using ERTACZO cream, tell your healthcare provider about all of your medical conditions, including if you:

    • have any allergies
    • are pregnant or plan to become pregnant. It is not known if ERTACZO cream will harm your unborn baby.
    • are breastfeeding or plan to breastfeed. It is not known if ERTACZO cream passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you use ERTACZO cream.

    Tell your healthcare provider about all of the medicinesyou take,including prescription and over-the-counter medicines, vitamins, and herbal supplements.

    How should I use ERTACZO cream?

    • Use ERTACZO cream exactly as your healthcare provider tells you to use it.
    • Use ERTACZO cream for the full treatment time, even if your symptoms improve.
    • If you take a bath or shower, dry the affected skin areas well before you apply ERTACZO cream.
    • Apply ERTACZO cream 2 times a day for 4 weeks to the affected skin areas between your toes and to the healthy skin around the affected areas.
    • Wash your hands after you apply ERTACZO cream.
    • Do not cover the treated skin areas with bandages unless your healthcare provider tells you to.

    What are the possible side effects of ERTACZO cream?

    The most common side effects of ERTACZO cream include:redness, itching, dry skin, burning, blistering, swelling, drainage, and skin tenderness at the treated skin areas. Tell your healthcare provider if you have any of these skin reactions.

    These are not all the possible side effects of ERTACZO cream.

    Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

    How should I store ERTACZO cream?

    • Store ERTACZO cream at room temperature between 68°F to 77°F (20°C to 25°C).
    • Keep ERTACZO cream and all medicines out of reach of children.

    General information about the safe and effective use of ERTACZO cream

    Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use ERTACZO cream for a condition for which it was not prescribed. Do not give ERTACZO cream to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about ERTACZO cream that is written for health professionals.

    What are the ingredients in ERTACZO cream?

    Active ingredient:sertaconazole nitrate

    Inactive ingredients:ethylene glycol, glyceryl isostearate, glycolized saturated glycerides, light mineral oil, methylparaben, polyethylene glycol palmitostearate, polyoxyethylened saturated glycerides, purified water, and sorbic acid


    Distributed by:
    Lacer Pharma, LLC
    Biloxi, MS 39532 USA

    Manufactured by:
    DPT Laboratories, Ltd.
    San Antonio, TX 78215

    ERTACZO is a trademark of Lacer Pharma, LLC

    141329

    This Patient Information has been approved by the U.S. Food and Drug Administration.
    Revised: 04/2024

  • PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – 60 g Carton

    NDC0187-5115-60

    ERTACZO ®
    (sertaconazole nitrate) cream, 2%

    Rx only

    For Topical Use Only - Not for Ophthalmic, Oral, or Intravaginal Use

    Net Wt. 60 g

    Tube ImageCarton Image

  • INGREDIENTS AND APPEARANCE
    ERTACZO 
    sertaconazole nitrate cream
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 73159-004
    Route of AdministrationTOPICAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    SERTACONAZOLE NITRATE (UNII: 1DV05410M5) (SERTACONAZOLE - UNII:72W71I16EG) SERTACONAZOLE NITRATE20 mg  in 1 g
    Inactive Ingredients
    Ingredient NameStrength
    ETHYLENE GLYCOL (UNII: FC72KVT52F)  
    GLYCERYL ISOSTEARATE (UNII: HYE7O27HAO)  
    LIGHT MINERAL OIL (UNII: N6K5787QVP)  
    METHYLPARABEN (UNII: A2I8C7HI9T)  
    SORBIC ACID (UNII: X045WJ989B)  
    PEG-6 STEARATE (UNII: 8LQC57C6B0)  
    GLYCOL STEARATE (UNII: 0324G66D0E)  
    PEG-32 STEARATE (UNII: 33GX5WQC0M)  
    WATER (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 73159-004-601 in 1 CARTON11/26/2024
    160 g in 1 TUBE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA02138511/26/2024
    Labeler - Lacer Pharma, LLC (117072266)
    Establishment
    NameAddressID/FEIBusiness Operations
    DPT Laboratories, Ltd.832224526manufacture(73159-004)

    • Trademark Results [Ertaczo]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    ERTACZO
    ERTACZO
    78125990 2893833 Live/Registered
    VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
    2002-05-03
    © 2025 FDA.report
    This site is not affiliated with or endorsed by the FDA.